Pemigatinib, a small molecule kinase inhibitor, selectively targets FGFR isoforms 1, 2 and 3, which, in preclinical studies, has resulted in anti-tumor activity in cells with FGFR alterations.
This study examines the influences of liver enzymes on the overall survival in a number of patients with intrahepatic cholangiocarcinoma (ICC).
Aspirin’s anti-inflammatory action is protective against another aggressive cancer: cholangiocarcinoma. Furthermore, it is beneficial regardless of daily use or dose.
New data from two clinical trials presented at the International Liver Congress 2013 demonstrated substantial improvements in the detection of both HCC and cholangiocarcinoma using diagnostic urine tests.
